# PAX5

## Overview
PAX5 is a gene that encodes the paired box 5 protein, a transcription factor pivotal in the development and differentiation of B-cells, a type of white blood cell essential for the adaptive immune response. The protein, also known as B-cell specific activator protein (BSAP), is characterized by a paired domain that facilitates DNA binding, enabling it to regulate the expression of genes critical for B-cell lineage commitment and function (Delogu2006Gene; PerezBorrajero2016Structural). PAX5 functions as both an activator and repressor of transcription, interacting with various proteins to modulate gene expression and maintain B-cell identity (Eberhard2000Transcriptional). Dysregulation of PAX5, through mutations or other genetic alterations, is associated with hematological malignancies, particularly B-cell acute lymphoblastic leukemia, underscoring its clinical significance in oncology (Nasri2022The; Jia2022PAX5).

## Structure
The PAX5 gene encodes a transcription factor crucial for B-cell development, known as the B-cell specific activator protein (BSAP). The protein structure of PAX5 includes a paired domain (PD) responsible for DNA binding, which is divided into two subdomains: the N-terminal domain (NTD) and the C-terminal domain (CTD). The NTD is dynamic and plays a role in discriminating between specific and non-specific DNA sites, while the CTD is more stable and capable of binding non-specific DNA sequences, facilitating the localization of PAX5 on genomic DNA (PerezBorrajero2016Structural).

The PD binds the major groove of DNA, with additional minor groove contacts provided by a β-hairpin and linker, which become ordered upon DNA binding, enhancing stability and affinity (PerezBorrajero2016Structural). PAX5 also contains an octapeptide motif and a transactivation domain, which are involved in its regulatory functions (Robichaud2004Human).

PAX5 undergoes alternative splicing, resulting in multiple isoforms with distinct transactivation properties. These isoforms can include or exclude exons 7, 8, and 9, leading to variations in the C-terminal region that affect their transactivation potential (Robichaud2004Human). The structural flexibility and stability of PAX5's domains are crucial for its role in transcriptional regulation and its association with oncogenic processes (PerezBorrajero2016Structural).

## Function
The PAX5 gene is a critical transcription factor involved in the development and differentiation of B-cells, which are essential components of the immune system. It plays a central role in B-cell lineage commitment by activating B-cell-specific genes and repressing genes inappropriate for B-cell development, thereby maintaining B-cell identity and function (Nasri2022The; Delogu2006Gene). PAX5 is active in the nucleus, where it regulates gene expression by binding to specific DNA sequences, influencing the transcription of genes involved in B-cell signaling and development (Pridans2008Identification).

PAX5 is essential for the progression of B-cell differentiation from hematopoietic stem cells to mature B-cells. It supports the expression of B-cell phenotypic markers and cooperates with other transcription factors to establish B-cell identity (Nasri2022The). PAX5 also plays a role in preventing the differentiation of other hematopoietic lineages by repressing lineage-inappropriate genes, ensuring that B-cells do not express genes that would lead them to differentiate into other cell types (Delogu2006Gene).

In healthy cells, PAX5 ensures the proper regulation of metabolic pathways and energy utilization, which are crucial for normal cell function and prevention of oncogenic transformation (Nasri2022The). Its expression is tightly controlled, and any dysregulation can lead to impaired B-cell development and function, highlighting its importance in maintaining normal immune function (Nasri2022The).

## Clinical Significance
Mutations and alterations in the PAX5 gene are significantly associated with various hematological malignancies, particularly B-cell acute lymphoblastic leukemia (B-ALL). PAX5 mutations, such as point mutations in the DNA-binding domain, can impair DNA binding and disrupt normal B-cell differentiation, contributing to leukemogenesis (Jia2022PAX5). The PAX5 P80R mutation is a notable example, defining a novel B-ALL subtype characterized by biallelic alterations and associated with a monocytic switch (Jia2022PAX5). 

PAX5 gene alterations, including deletions, gains, and rearrangements, are prevalent in childhood precursor B-cell acute lymphoblastic leukemia, with some patients exhibiting bi-allelic impairment (Stasevich2015PAX5). These genetic changes can lead to aberrant PAX5 expression and are linked to higher white blood cell counts in affected individuals (Stasevich2015PAX5).

In addition to B-ALL, PAX5 mutations are implicated in other B-cell malignancies, such as diffuse large B-cell lymphoma and chronic lymphocytic leukemia. These mutations often result in dominant negative effects or create fusion proteins that alter transcriptional activities, further contributing to cancer progression (Nasri2022The). The gene's role in cancer is modulated by epigenetic modifications, such as promoter hypermethylation, which can inhibit its tumor-suppressive functions (Nasri2022The).

## Interactions
PAX5 is a transcription factor that plays a crucial role in B-cell development and interacts with various proteins and nucleic acids to regulate gene expression. It functions as both an activator and repressor by forming complexes with other proteins. PAX5 interacts with members of the Groucho corepressor family, particularly Grg4 (TLE4), to mediate transcriptional repression. This interaction involves the N-terminal Q and central SP regions of Grg4 and the octapeptide motif and C-terminal transactivation domain of PAX5, which is essential for B-lineage commitment by suppressing alternative cell fates (Eberhard2000Transcriptional).

In the context of B-cell acute lymphoblastic leukemia (B-ALL), PAX5 is part of a transcription factor network that includes IKZF1, RUNX1, and EBF1. These proteins share many target genes, and PAX5 mutations are often found alongside mutations in these factors, suggesting a collaborative role in leukemogenesis (Okuyama2019PAX5). PAX5 also interacts with DNA, with its N-terminal domain setting DNA-binding specificity, which is crucial for its regulatory functions (PerezBorrajero2016Structural). Additionally, PAX5 can recruit Ets proto-oncogene family proteins to form functional ternary complexes on B-cell-specific promoters, highlighting its role in cell-type-specific transcription regulation (Fitzsimmons1996Pax5).


## References


[1. (Stasevich2015PAX5) Irina Stasevich, Sarah Inglott, Nicola Austin, Steve Chatters, Jane Chalker, Dilys Addy, Carryl Dryden, Philip Ancliff, Anthony Ford, Owen Williams, and Helena Kempski. <scp>pax</scp>5 alterations in genetically unclassified childhood precursor b‐cell acute lymphoblastic leukaemia. British Journal of Haematology, 171(2):263–272, June 2015. URL: http://dx.doi.org/10.1111/bjh.13543, doi:10.1111/bjh.13543. This article has 11 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/bjh.13543)

[2. (Eberhard2000Transcriptional) Dirk Eberhard, Gerardo Jiménez, Barry Heavey, and Meinrad Busslinger. Transcriptional repression by pax5 (bsap) through interaction with corepressors of the groucho family. The EMBO Journal, 19(10):2292–2303, May 2000. URL: http://dx.doi.org/10.1093/emboj/19.10.2292, doi:10.1093/emboj/19.10.2292. This article has 190 citations.](https://doi.org/10.1093/emboj/19.10.2292)

[3. (Nasri2022The) Parinaz Nasri Nasrabadi, Danick Martin, Ehsan Gharib, and Gilles A. Robichaud. The pleiotropy of pax5 gene products and function. International Journal of Molecular Sciences, 23(17):10095, September 2022. URL: http://dx.doi.org/10.3390/ijms231710095, doi:10.3390/ijms231710095. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms231710095)

[4. (Okuyama2019PAX5) Kazuki Okuyama, Tobias Strid, Jacob Kuruvilla, Rajesh Somasundaram, Susana Cristobal, Emma Smith, Mahadesh Prasad, Thoas Fioretos, Henrik Lilljebjörn, Shamit Soneji, Stefan Lang, Jonas Ungerbäck, and Mikael Sigvardsson. Pax5 is part of a functional transcription factor network targeted in lymphoid leukemia. PLOS Genetics, 15(8):e1008280, August 2019. URL: http://dx.doi.org/10.1371/journal.pgen.1008280, doi:10.1371/journal.pgen.1008280. This article has 37 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1371/journal.pgen.1008280)

[5. (Fitzsimmons1996Pax5) D Fitzsimmons, W Hodsdon, W Wheat, S M Maira, B Wasylyk, and J Hagman. Pax-5 (bsap) recruits ets proto-oncogene family proteins to form functional ternary complexes on a b-cell-specific promoter. Genes &amp; Development, 10(17):2198–2211, September 1996. URL: http://dx.doi.org/10.1101/gad.10.17.2198, doi:10.1101/gad.10.17.2198. This article has 191 citations.](https://doi.org/10.1101/gad.10.17.2198)

[6. (Robichaud2004Human) Gilles A. Robichaud, Michel Nardini, Mark Laflamme, Miroslava Cuperlovic-Culf, and Rodney J. Ouellette. Human pax-5 c-terminal isoforms possess distinct transactivation properties and are differentially modulated in normal and malignant b cells. Journal of Biological Chemistry, 279(48):49956–49963, November 2004. URL: http://dx.doi.org/10.1074/jbc.M407171200, doi:10.1074/jbc.m407171200. This article has 58 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M407171200)

[7. (Delogu2006Gene) Alessio Delogu, Alexandra Schebesta, Qiong Sun, Katharina Aschenbrenner, Thomas Perlot, and Meinrad Busslinger. Gene repression by pax5 in b cells is essential for blood cell homeostasis and is reversed in plasma cells. Immunity, 24(3):269–281, March 2006. URL: http://dx.doi.org/10.1016/j.immuni.2006.01.012, doi:10.1016/j.immuni.2006.01.012. This article has 275 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.immuni.2006.01.012)

[8. (PerezBorrajero2016Structural) Cecilia Perez-Borrajero, Mark Okon, and Lawrence P. McIntosh. Structural and dynamics studies of pax5 reveal asymmetry in stability and dna binding by the paired domain. Journal of Molecular Biology, 428(11):2372–2391, June 2016. URL: http://dx.doi.org/10.1016/j.jmb.2016.04.004, doi:10.1016/j.jmb.2016.04.004. This article has 12 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.jmb.2016.04.004)

[9. (Jia2022PAX5) Zhilian Jia and Zhaohui Gu. Pax5 alterations in b-cell acute lymphoblastic leukemia. Frontiers in Oncology, October 2022. URL: http://dx.doi.org/10.3389/fonc.2022.1023606, doi:10.3389/fonc.2022.1023606. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2022.1023606)

[10. (Pridans2008Identification) Clare Pridans, Melissa L. Holmes, Matthew Polli, James M. Wettenhall, Aleksandar Dakic, Lynn M. Corcoran, Gordon K. Smyth, and Stephen L. Nutt. Identification of pax5 target genes in early b cell differentiation. The Journal of Immunology, 180(3):1719–1728, February 2008. URL: http://dx.doi.org/10.4049/jimmunol.180.3.1719, doi:10.4049/jimmunol.180.3.1719. This article has 115 citations.](https://doi.org/10.4049/jimmunol.180.3.1719)